Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Kevin M. Slawin"'
Autor:
MyLinh T. Duong, Matthew R. Collinson-Pautz, Eva Morschl, An Lu, Slawomir P. Szymanski, Ming Zhang, Mary E. Brandt, Wei-Chun Chang, Kelly L. Sharp, Steven M. Toler, Kevin M. Slawin, Aaron E. Foster, David M. Spencer, J. Henri Bayle
Publikováno v:
Molecular Therapy: Oncolytics, Vol 12, Iss , Pp 124-137 (2019)
Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insuffici
Externí odkaz:
https://doaj.org/article/2fbebd3dad654aee828c680d5ac36e2b
Autor:
David M. Spencer, Kevin M. Slawin, Jonathan M. Levitt, Jianghong Jiang, Brent A. Hanks, Mamatha R. Seethammagari, Natalia Lapteva
Supplementary Figures 1-8 from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d40bc1d83650af2e47796d414ddef6
https://doi.org/10.1158/0008-5472.22370157.v1
https://doi.org/10.1158/0008-5472.22370157.v1
Autor:
David M. Spencer, Kevin M. Slawin, Jonathan M. Levitt, Jianghong Jiang, Brent A. Hanks, Mamatha R. Seethammagari, Natalia Lapteva
Supplementary Methods from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081e453fe644b5223f3da3f8d9049381
https://doi.org/10.1158/0008-5472.22370154
https://doi.org/10.1158/0008-5472.22370154
Autor:
David M. Spencer, Kevin M. Slawin, Rama D. Gangula, Annie Z. Luo, Weitao Song, Xiuqin Zhao, Smruti A. Desai, Ekaterina Yu. Nikitina
Supplementary Figures 1-4 from Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52bb328d6d2d7bacf62502c97729ac29
https://doi.org/10.1158/0008-5472.22363419.v1
https://doi.org/10.1158/0008-5472.22363419.v1
Autor:
David M. Spencer, Kevin M. Slawin, Rama D. Gangula, Annie Z. Luo, Weitao Song, Xiuqin Zhao, Smruti A. Desai, Ekaterina Yu. Nikitina
To establish optimized conditions for immunity against prostate cancer, we compared the efficacy of multiple approaches in autochthonous and s.c. transgenic adenocarcinoma of the mouse prostate (TRAMP)-based models. Mice immunized with interleukin (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2495c69edcdf2a37433a8f6a4a0e28c6
https://doi.org/10.1158/0008-5472.c.6493707
https://doi.org/10.1158/0008-5472.c.6493707
Autor:
David M. Spencer, Kevin M. Slawin, Jonathan M. Levitt, Jianghong Jiang, Brent A. Hanks, Mamatha R. Seethammagari, Natalia Lapteva
Despite the potency of dendritic cells (DC) as antigen-presenting cells for priming adaptive immunity, DC-based cancer vaccines have been largely insufficient to effectively reduce tumor burden or prevent tumor progression in most patients. To enhanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d8d4a3e1d847b2100fd17c246bc3df9
https://doi.org/10.1158/0008-5472.c.6496296.v1
https://doi.org/10.1158/0008-5472.c.6496296.v1
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0164547 (2016)
Therapeutic DNA-based vaccines aim to prime an adaptive host immune response against tumor-associated antigens, eliminating cancer cells primarily through CD8+ cytotoxic T cell-mediated destruction. To be optimally effective, immunological adjuvants
Externí odkaz:
https://doaj.org/article/3f0556840842454e81910e8ebd19bab6
Autor:
An Lu, Kelly L. Sharp, Wei-Chun Chang, Kevin M. Slawin, Slawomir P. Szymanski, Steven M. Toler, Ming Zhang, Eva Morschl, David M. Spencer, Matthew R. Collinson-Pautz, My Linh T. Duong, J. Henri Bayle, Mary E. Brandt, Aaron E. Foster
Publikováno v:
Molecular Therapy: Oncolytics, Vol 12, Iss, Pp 124-137 (2019)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insuffici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea3ccbe3a4f7ff4b8f73320ec846449
http://www.sciencedirect.com/science/article/pii/S2372770518300469
http://www.sciencedirect.com/science/article/pii/S2372770518300469
Autor:
Aaron E. Foster, Mary E. Brandt, Kevin M. Slawin, David M. Spencer, Matthew R. Collinson-Pautz, Pei-Yi Lin, Mariam Khalil, Nicholas P. Shinners, My Linh T. Duong, J. Henri Bayle, Aruna Mahendravada, Wei-Chun Chang, Ming Zhang, An Lu, Jeannette Crisostomo
Publikováno v:
Leukemia
Successful adoptive chimeric antigen receptor (CAR) T-cell therapies against hematological malignancies require CAR-T expansion and durable persistence following infusion. Balancing increased CAR-T potency with safety, including severe cytokine-relea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e30e133078c58b79fdbde0dbc893bc7
https://doi.org/10.1038/s41375-019-0417-9
https://doi.org/10.1038/s41375-019-0417-9
Autor:
Mamatha Seethammagari, John McMannis, David M. Spencer, Kevin M. Slawin, Annemarie Moseley, Guru Sonpavde, Joan M C Bull, Theresa K. Dancsak, Natasha Lapteva, Victoria E Hawkins, Yu Bai, Jonathan M. Levitt
Publikováno v:
Cancer Immunology, Immunotherapy. 66:1345-1357
This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC). To manufacture BPX101, APCs colle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d831c0f1ddd7f2c36b29c1cc078528f
https://doi.org/10.1007/s00262-017-2027-6
https://doi.org/10.1007/s00262-017-2027-6